Print

National Institutes of Health (NIH) Data Suggests MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.)'s Stem Cell is Unique From Competitor Stem Cells  
10/10/2012 8:48:00 AM

SAN DIEGO--(BUSINESS WIRE)--Medistem Inc. (PINKSHEETS: MEDS) announced today a peer-reviewed publication led by NIH scientists demonstrating that the company’s Endometrial Regenerative Cells (ERC) possess a unique genetic signature associated with production of new blood vessels (angiogenesis). “The demonstration by an independent group that ERC possess a unique gene signature compared to other stem cells, and that the gene signature is associated with production of new blood vessels, is a strong validation for our programs,” said Dr. Thomas Ichim, President and CSO of Medistem. “These data support original publications by our group and others that have demonstrated ERC appear to be nature's regenerative powerhouse for production of new blood vessels.”